Pomerantz Law Firm has initiated class action litigation against Vistagen Therapeutics, Inc. following a significant decline in the company's stock price after negative clinical trial results. On December 17, 2025, Vistagen's shares fell 80.25% after the company announced that its PALISADE-3 Phase 3 trial for intranasal fasedienol failed to meet its primary endpoint for treating social anxiety disorder, triggering the legal action.
The lawsuit represents investors who experienced losses during the period surrounding the trial announcement. Shareholders who hold or held Vistagen securities during the relevant timeframe may be eligible to participate in the class action. Legal representatives are accepting claims from affected investors and have established March 16, 2026, as the deadline for investors to contact the firm regarding potential lead plaintiff status.
Pomerantz Law Firm has also filed separate class action cases against China Liberal Education Holdings Limited and Smart Digital Group Limited. Investors with documented losses are encouraged to reach out to the firm to discuss their eligibility and potential recovery options under the securities litigation framework.